Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.98 |
| ▸ | DRD3 | P35462 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 3/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | DRD2 | P14416 | 3/20 | 0.98 |
| ▸ | HRH2 | P25021 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR5A | P47898 | 1/20 | 0.98 |
| ▸ | HTR6 | P50406 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyzine SCHEMBL491323 | 1.00 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL41448 | 1.00 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL4492 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL383277 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL3061159 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL4491 | 0.99 | DRD3 (1.00) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Etodroxizine SCHEMBL9064076 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Etodroxizine SCHEMBL668191 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL28290521 | 0.98 | DRD3 (0.98) | DRD3HRH1USP2KCNH2CYP2D6 | |
| Hydroxyzine SCHEMBL15532242 | 0.96 | DRD3 (0.95) | DRD3HRH1USP2KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3081 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178804-B2 | Salts of cycloserine compounds and applications thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2024-12-31 | — | — | US | claimed |
| CN-118021984-A | Compound external preparation, preparation method and application thereof | 南方医科大学 | 2024-05-14 | — | — | CN | claimed |
| CN-114019076-B | Method for simultaneously measuring 5 components in compound hyprolfsteaine dechlorinated hydroxyzine capsules | 苏州市药品检验检测研究中心 | 2024-04-09 | — | — | CN | claimed |
| WO-2022241985-A1 | USE OF H1 HISTAMINE RECEPTOR ANTAGONIST IN PREPARATION OF DRUG FOR TREATING GLIOMA | 温州医科大学附属第一医院 | 2022-11-24 | — | — | WO | claimed |
| CN-114414707-B | Method and kit for detecting 19 drugs and metabolites thereof in blood by liquid chromatography tandem mass spectrometry | 北京和合医学诊断技术股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114414707-A | Method and kit for detecting 19 drugs and metabolites thereof in blood by liquid chromatography tandem mass spectrometry | 北京和合医学诊断技术股份有限公司 | 2022-04-29 | — | — | CN | claimed |
| US-20220047561-A1 | SALTS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-02-17 | — | — | US | claimed |
| US-20220031664-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTIEMETICS AND ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USING THE SAME FOR ANESTHESIOLOGICAL APPLICATIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2022-02-03 | — | — | US | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | claimed |
| CN-113384702-A | Application of H1 histamine receptor antagonist in preparation of medicine for treating glioma | 温州医科大学附属第一医院 | 2021-09-14 | — | — | CN | claimed |
| WO-2002026244-A2 | COMPOSITIONS AND METHODS OF USE FOR EXTRACTS OF RUTACEAE PLANTS | NEXT PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| US-20010051184-A1 | METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES | NEUVOLA II, LLC | 2001-12-13 | — | — | US | claimed |
| US-6312728-B1 | DRUG DELIVERY DEVICE WITH CORE, ENTERIC POLYMER AND COATING | CASCADE DEVELOPMENT, INC. | 2001-11-06 | — | — | US | claimed |
| EP-1094790-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATION | Cascade Development, Inc. (US) | 2001-05-02 | — | — | EP | claimed |
| WO-2000070949-A1 | METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES | HENG MADALENE C Y (US) | 2000-11-30 | — | — | WO | claimed |
| WO-2000001369-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATION | CASCADE DEVELOPMENT, INC. (US) | 2000-01-13 | — | — | WO | claimed |
| US-5968554-A | DRUG DELIVERY WITH CORE AND PROTECTIVE COATING | CASCADE DEVELOPMENT, INC. A SUBSIDIARY OF CARDINAL HEALTH, INC. (US) | 1999-10-19 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5053396-A | For treatment of symptoms associated with excessive alcohol intake, analgesic; nicotinamide or nicotinamide adenine dinucleotide | BLASS DAVID H (GB) | 1991-10-01 | — | — | US | claimed |
| US-4889850-A | Treatment of colic and teething | THORNFELDT CARL R (US) | 1989-12-26 | — | — | US | claimed |